2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访

2023-09-05 欧洲肿瘤内科学会 Ann Oncol 发表于上海

指南主要内容涵盖了胰腺癌的诊断、分期,风险评估、治疗、疾病监测和随访。所有建议均基于现有的科学数据和集体专家意见。

中文标题:

2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访

英文标题:

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

发布机构:

欧洲肿瘤内科学会

发布日期:

2023-09-05

简要介绍:

该指南涵盖诊断、分期、风险评估、治疗、疾病监测和随访。

多学科专家作者团队来自欧洲、亚洲和美国的不同机构和国家。

建议基于现有的科学数据和作者的集体专家意见。

ESMO-MCBS 和 ESCAT 评分为治疗选择(包括靶向治疗)提供了不同程度的证据。

在临床实践中,提供的所有建议都需要与患者以共同决策的方式进行讨论。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=240451c003331954, title=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访, enTitle=Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, guiderFrom= Ann Oncol, authorId=0, author=, summary=指南主要内容涵盖了胰腺癌的诊断、分期,风险评估、治疗、疾病监测和随访。所有建议均基于现有的科学数据和集体专家意见。 , cover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Tue Sep 05 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<p class="ce-list--remove-bullets__list-item__text">该指南涵盖诊断、分期、风险评估、治疗、疾病监测和随访。</p> <p class="ce-list--remove-bullets__list-item__text">多学科专家作者团队来自欧洲、亚洲和美国的不同机构和国家。</p> <p class="ce-list--remove-bullets__list-item__text">建议基于现有的科学数据和作者的集体专家意见。</p> <p class="ce-list--remove-bullets__list-item__text">ESMO-MCBS 和 ESCAT 评分为治疗选择(包括靶向治疗)提供了不同程度的证据。</p> <p class="ce-list--remove-bullets__list-item__text">在临床实践中,提供的所有建议都需要与患者以共同决策的方式进行讨论。</p>, tagList=[TagDto(tagId=718, tagName=胰腺癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=718, articleKeyword=胰腺癌, articleKeywordNum=6, guiderKeywordId=718, guiderKeyword=胰腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7294, appHits=151, showAppHits=0, pcHits=717, showPcHits=7143, likes=0, shares=27, comments=4, approvalStatus=1, publishedTime=Fri Sep 08 16:00:00 CST 2023, publishedTimeString=2023-09-05, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Fri Sep 08 13:41:32 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Sat Jan 06 09:06:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf)])
2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
    2023-10-09 苏日娜 来自内蒙古

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
    2023-09-09 JZ Yang 来自浙江省

    感谢分享

    0

拓展阅读

胰腺癌死亡风险直降57%!阿司匹林为糖尿病群体带来防癌曙光

胰腺癌恶性程度高,2 型糖尿病患者患胰腺癌风险高,传统筛查手段受限。香港大学研究发现新诊断 T2DM 患者长期服阿司匹林可降胰腺癌发病、相关死亡和全因死亡风险,揭示其机制并提应用建议。

PD-L1蛋白表达和肿瘤突变负荷(TMB)助力晚期胰腺癌免疫治疗获益人群筛选,指导精准治疗

免疫检查点抑制剂疗法对胰腺癌基本无效,但两例经传统治疗无效或复发的晚期胰腺癌患者,经评估 CPS/TPS 或 TMB 后采用该疗法获持久缓解,提示相关评估对胰腺癌治疗有指导意义。

病理干货 | 精准医学时代下胰腺癌的靶向治疗

本文将聚焦胰腺癌的靶向治疗进展,并探讨精准医学时代下胰腺癌的治疗前沿。

专家论坛|张太平:胰腺癌临床前肿瘤模型的建立与应用进展

本文阐述了用于胰腺癌临床前肿瘤研究的各类模型的特点及应用进展,分析并探讨了人源性组织异种移植、条件重编程、患者来源的类器官等模型的历史发展、研究现状和优缺点。

述评|赵玉沛:胰腺癌诊治的进展与思考

本文就胰腺癌诊治中的热点话题,结合最新的循证医学证据,探讨胰腺癌诊治的未来发展方向。

Cell Res:清华大学葛亮/张敏/与广州医科大学冯杜合作揭示RAS突变肿瘤过程中特异性自噬的调控机制

研究确定了一种由致癌KRAS表达诱导的非经典自噬形式,称为RAS诱导的通过ATG8ylation(RINCAA)诱导的非经典自噬。

2010ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

胰腺癌诊疗规范(2011年版)

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-10-14

2012 胰腺癌经动脉灌注化疗指南(草案)

中华医学会放射学分会介入学组 · 2012-05-30

2012 ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2013 胰腺癌多学科综合治疗协作组专家共识

中华医学会肿瘤学分会 · 2013-05-01